Literature DB >> 8965183

SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT.

A Abi-Dargham1, M S Gandelman, G A DeErausquin, Y Zea-Ponce, S S Zoghbi, R M Baldwin, M Laruelle, D S Charney, P B Hoffer, J L Neumeyer, R B Innis.   

Abstract

Iodine-123-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane (beta-CIT) is a useful SPECT tracer for imaging the dopamine transporter. Its slow kinetics, however, necessitate imaging on the day after the injection. Two N-omega-fluoroalkyl analogs of beta-CIT, the fluoropropyl and fluoroethyl compounds (beta-CIT-FP and beta-CIT-FE, respectively), characterized by faster kinetics in baboons, were tested in humans as potential tracers for the dopamine transporter. Four healthy volunteers were injected with [123I]-beta-CIT-FP and another four were injected with [123I]beta-CIT-FE. SPECT data were acquired for 1149 +/- 590 min and 240 +/- 30 min, respectively. Both tracers demonstrated high brain uptake (6.37% +/- 0.37% and 7.8% +/- 1.5% of the injected dose, respectively). Activity concentrated with time in the striatal area, reaching a peak within 30 min, with little or no washout for [123I]beta-CIT-FP and a faster washout for [123I]beta-CIT-FE (14.7% +/- 6.9%). Occipital and midbrain activity showed similar patterns, displaying a peak within 15 min and rapid washout, followed by stable levels at approximately 100 min for both tracers. The ratio of peak specific striatal-to-peak specific midbrain activity was 9.1 +/- 1.8 for [123I]beta-CIT-FP and 7.7 +/- 0.7 for [123I]beta-CIT-FE, showing high in vivo selectivity for the dopamine transporter. These preliminary results suggest that both compounds could be used as SPECT (labeled with 123I) or PET (labeled with 18F) radiotracers to image the dopamine transporters in the living human brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8965183

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  Hydrocephalus-induced neuroleptic malignant-like syndrome with reduced dopamine transporters.

Authors:  Daniel Jussen; Christian Sprung; Ralph Buchert; Johann Sebastian Braun
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

2.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Authors:  J Booij; G Tissingh; G J Boer; J D Speelman; J C Stoof; A G Janssen; E C Wolters; E A van Royen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

3.  Comments on Eusebio et al.: Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects.

Authors:  Jan Booij; Elsmarieke van de Giessen; Swen Hesse; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-24       Impact factor: 9.236

4.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

5.  Preserved Extrastriatal 123I-FP-CIT Binding in Scans Without Evidence of Dopaminergic Deficit (SWEDD).

Authors:  Nicolas Nicastro; Pierre R Burkhard; Valentina Garibotto
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

6.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

7.  Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use?

Authors:  Habib Zaidi; Georges El Fakhri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07       Impact factor: 9.236

8.  Dystrophic serotonergic axons in neurodegenerative diseases.

Authors:  Efrain C Azmitia; Ralph Nixon
Journal:  Brain Res       Date:  2008-04-07       Impact factor: 3.252

9.  Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis.

Authors:  S V Faraone; T J Spencer; B K Madras; Y Zhang-James; J Biederman
Journal:  Mol Psychiatry       Date:  2013-09-24       Impact factor: 15.992

10.  Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy.

Authors:  Michael Nocker; Klaus Seppi; Sylvia Boesch; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler
Journal:  Mov Disord Clin Pract       Date:  2016-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.